Gao Hongmei, a director of BIOTEST BIOTECH, completed a reduction in holdings, with a total reduction of 560,000 shares

Zhitong
2025.05.27 08:39
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, BIOTEST BIOTECH announced that the share reduction plan of the company's director and senior management Gao Hongmei has been completed, with a total of 560,000 shares sold through centralized bidding, accounting for 0.5250% of the company's total share capital

According to the Zhitong Finance APP, BIOTEST BIOTECH (688767.SH) announced that the share reduction plan of the company's director and senior management Gao Hongmei has been completed. She has cumulatively reduced her holdings by 560,000 shares through centralized bidding, accounting for 0.5250% of the company's total share capital

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.